Endoscopic ultrasound-guided liver biopsy using a dynamic wet technique
Official title: Efficacy of Endoscopic Ultrasound Guided Liver Biopsy Using Dynamic Wet Technique
Run by Sohag University · NCT06833619 · Data updated 2026-11-12
This study is testing a new way to do liver biopsies using ultrasound to see if it makes the procedure safer and more accurate for patients with different health conditions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag) |
| Status | Recruiting |
| Started | December 1, 2024 |
| Main results expected | January 1, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | February 19, 2025 |
| Trial ID | NCT06833619 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults requiring a liver biopsy due to altered liver function tests.
✕Probably not a fit
Patients on anti-platelet or anticoagulant therapy, those with moderate-to-gross ascites, or severe liver disease (Child C cirrhosis) may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy of endoscopic ultrasound-guided liver biopsy (EUS-LB) using a dynamic wet technique, which aims to improve the safety and accuracy of liver biopsies. The procedure allows for real-time visualization of the needle entering the liver, minimizing the risk of injury to intrahepatic vessels and bile ducts. It is particularly beneficial for patients with altered liver function tests and can be performed safely in individuals with higher international normalized ratios (INR) compared to traditional methods. The study focuses on assessing the outcomes of this technique in various patient populations, including those who are obese or pregnant.
Why it matters
Potential benefit: If successful, this technique could provide a safer and more effective method for obtaining liver biopsies, leading to better diagnostic outcomes for patients.
How similar studies have gone: While EUS-LB has shown promise in previous studies, its widespread use is still limited, indicating that this approach is not yet fully established in clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The participants of the study were adults in need of liver biopsy for the evaluation of Altered liver function test Exclusion Criteria: * Using anti-platelets or anticoagulants within the last 5days * Inability to provide informed consent * Moderate-to-gross ascites * Child C cirrhosis * INR more than 2.01 * Platelet count less than 50,000/µL3
Where it's running
-
Sohag University
Sohag, Egypt Recruiting
Study contacts
- Study coordinator: Sara Elbadry Elrabie, master
- Email: elbadrysara615@gmail.com
- Phone: 01023941334
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Trauma registry at Sohag University Hospital
This study tests the creation of a trauma registry in the emergency department to collect data on injured adults admitted with polytrauma at Sohag University Hospital.
-
Prevalence of Myocardial Bridging and its relation to Coronary Plaques on MDCT
This study tests how common myocardial bridging is and whether it relates to coronary plaque in patients undergoing coronary CT angiography.
-
Septoplasty: see if it changes headache symptoms
This study tests whether septoplasty can change headache severity in adults with septal deviation and headache.
-
Predicting SLE Flares with Patient Reports and Machine Learning
Aims to test a low-cost, patient-reported outcome–based machine learning tool to see if it can detect lupus flares early and support care, especially in settings with limited resources.
-
Is geographic mismatch linked to short-term major heart problems after long drug-eluting stent placement?
This study checks whether geographic mismatch can predict short-term major adverse cardiovascular events after a long drug-eluting stent is placed in the coronary arteries.
-
Biomarkers to predict no-reflow after opening the heart’s artery in STEMI patients
This study tests whether immune-inflammatory and metabolic biomarkers can predict coronary no-reflow after primary PCI in adults with STEMI.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.